Aligos Therapeutics, Inc. ((ALGS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Aligos Therapeutics, Inc. is conducting a Phase 2 study titled ‘A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)’. The study aims to assess the efficacy and safety of ALG-000184, a potential new treatment for chronic Hepatitis B, compared to the existing treatment, Tenofovir Disoproxil Fumarate (TDF). This study is significant as it could lead to improved treatment options for patients with chronic Hepatitis B.
Intervention/Treatment: The study tests two oral drugs: ALG-000184 and TDF. ALG-000184 is an experimental drug, while TDF is an active comparator. Both are administered as 300 mg tablets once daily for 48 weeks, followed by an open-label treatment with ALG-000184 for an additional 48 weeks.
Study Design: This is a randomized, double-blind, active-controlled, multicenter study with a parallel intervention model. The study uses quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded. The primary purpose of the study is treatment-focused.
Study Timeline: The study began on April 22, 2025, with the latest update submitted on September 16, 2025. These dates are crucial as they mark the study’s progress and ensure transparency in its ongoing status.
Market Implications: The progress of this study could significantly impact Aligos Therapeutics’ stock performance and investor sentiment. Positive results may enhance the company’s market position, especially in the competitive field of Hepatitis B treatments. Investors should monitor updates closely as they could influence market dynamics and competitive strategies within the pharmaceutical industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.